Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will collect blood samples and tumor tissue from adults with relapsed small-cell lung cancer who are being treated with a DLL3 bispecific T cell engager. The study will perform comprehensive multi-omic analyses—genomics, transcriptomics, proteomics—and link these data with clinical outcomes to understand resistance mechanisms and identify potential treatment vulnerabilities. Primary goal is to assess whether paired tumor samples and serial blood collections are feasible in this setting. Secondary goals include characterizing longitudinal tumor markers, evaluating concordance between plasma and tissue findings, and exploring associations with treatment responses. No experimental therapy is given; the study observes standard-of-care treatment alongside biospecimen collection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 years of age or older
2. Confirmed pathologic diagnosis of active SCLC or neuroendocrine cancer.
3. Relapsed small cell lung cancer (SCLC) planning to receive commercial DLL3 bispecific T cell engager.
4. Willing to provide informed consent.
5. Willing to provide blood samples and undergo tissue biopsy at various time points throughout the study, collected in concurrence with treatment cycles and/or imaging visits
6. Patients with multiple primary malignancies, recurrent lung cancer, or mixed histology are not excluded.
7. Patients who have contraindications or are unable to receive immunotherapy will be eligible for the study, and their samples will be used for comparison and control.

Exclusion Criteria:

1. Prisoners or incarcerated patients
2. Those with cognitive impairments lacking decision-making capacity are excluded.
3. There will be no specific restrictions with respect to performance status, organ function, or prior/concurrent modes of therapy other than that the patient must be able to tolerate venipuncture and any planned interventional radiology or surgical procedures deemed necessary by their treating physicians.

Where it's running

• Ohio State University Comprehensive Cancer Center
  Columbus, Ohio, United States Recruiting

Study contacts

• Principal investigator: Asrar Alahmadi, MBBS, MAS-CR — Ohio State University Comprehensive Cancer Center
• Study coordinator: The Ohio State University Comprehensive Cancer Center
• Email: OSUCCCClinicaltrials@osumc.edu
• Phone: 800-293-5066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08634404 with or without chemotherapy for adults with transformed small cell lung cancer

  This will try the experimental drug PF-08634404 by itself and together with chemotherapy in adults whose EGFR-mutated non-small cell lung cancer has turned into transformed small cell lung cancer.

  Recruiting at 55 sites Phase 2 Pfizer · Duarte, California and 60 other locations · NCT07476287

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Treatment of solid tumors or lymphoma with VMD-928

  This study is testing a new oral medication called VMD-928 to see if it can help adults with advanced solid tumors or lymphoma that haven't improved with standard treatments.

  Recruiting at 13 sites Phase 1/2 VM Oncology, LLC · Santa Rosa, California and 12 other locations · NCT03556228

• 68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

  This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07914764

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• Exploration of whole-brain radiotherapy with PD-1 inhibitors for brain injury in SCLC

  This study tests whether adding PD-1 inhibitors to chemotherapy and prophylactic brain irradiation helps some small cell lung cancer patients protect the brain.

  Recruiting Guizhou Medical University · Guiyang, Guizhou · NCT07905937

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.